Peptides · Peptide comparison
Chonluten vs Crystagen
Bronchopulmonary tripeptide bioregulator (Glu-Asp-Gly) that restores respiratory epithelial function through DNA minor groove binding at ATTTC sequences, induces TNF tolerance in alveolar macrophages reducing inflammatory cytokines by up to 6-fold, and normalizes bronchial mucosa differentiation markers in aging lung tissue
Immunogeroprotective tripeptide bioregulator (Glu-Asp-Pro) that optimally stimulates thymic epithelial cell proliferation at 200 ng/mL, suppresses thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, and contributed to a 4.1-fold mortality reduction in a 266-person 6-8 year clinical study when combined with complementary pineal peptides
- Immune
- Immune
At a glance
Quick comparison
Efficacy
Benefit ratings
Respiratory Tissue Repair
Lung Inflammation Control
Age-Related Lung Protection
Immune Rejuvenation
Healthy Aging
Cancer Defense
Technical data
Compound specifications
Chonluten
- Molecular formula
- C11H17N3O8
- Molecular weight
- 319.27 g/mol
- Half-life
- Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids
- Bioavailability
- Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure
- CAS number
- 75007-24-8
Crystagen
- Molecular formula
- C14H21N3O8
- Molecular weight
- 359.3 g/mol
- Half-life
- Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids
- Bioavailability
- Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure
- CAS number
- Not assigned (patented as immunogeroprotective peptide, US8057810B2)
Protocols
Dosing compared
Chonluten
Subcutaneous
- 5-10 mgOnce daily · 10-20 days per courseFor the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6]
Oral
- 1-2 capsules1-2 times daily with meals · 10-30 day course, repeated 2-3 times per yearThe oral capsule plan used in practice for this bronchopulmonary peptide supplement. [6]
Crystagen
Subcutaneous
- 200-400 mcgOnce daily · 10-20 days per course, repeated every 4-6 monthsFor the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6]
Intramuscular
- 200-400 mcgOnce daily · 10-20 days per course, repeated every 4-6 monthsCan also be given as an intramuscular injection at a similar dose, used in research practice. [6]
Oral
- 1-2 capsules (10 mg each)1-2 times daily with meals · 10-30 day course, repeated every 4-6 monthsThe oral capsule plan used in practice. Each Cytogen capsule holds 10 mg, delivering about 200-400 mcg of active peptide per dose. [6]
Applications
Best suited for
Chonluten
- Respiratory health restoration in aging individuals with declining lung function
- Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Chronic bronchopulmonary conditions requiring tissue-level regenerative support
- Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
- Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Geroprotective therapy for lung tissue preservation in elderly populations
- Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Crystagen
- Restoring thymic function and immune competence in aging individuals with immune senescence
- Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
- Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Supporting immune function during and after illness recovery
- Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence
- Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Chonluten
Common
- Injection site reaction
- Mild fatigue
- Transient respiratory changes
- Mild headache
Uncommon
- Flu-like symptoms
Serious
- No documented serious adverse effects
Crystagen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Minor digestive changes
Uncommon
- Flu-like symptoms
Serious
- No documented serious adverse effects
Research status
Safety & evidence
Chonluten
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active pulmonary infections requiring immediate medical treatment
- Severe immunosuppression without medical supervision — immunomodulatory effects may be unpredictable
Crystagen
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active autoimmune disease in flare without physician supervision
- Organ transplant recipients on immunosuppression — potential interference with immunosuppressive regimens
Decision guide
Which is right for you?
Chonluten
Choose Chonluten if…
- Respiratory health restoration in aging individuals with declining lung function
- Chronic bronchopulmonary conditions requiring tissue-level regenerative support
- Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
- Geroprotective therapy for lung tissue preservation in elderly populations
Crystagen
Choose Crystagen if…
- Restoring thymic function and immune competence in aging individuals with immune senescence
- Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
- Supporting immune function during and after illness recovery
- Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence